WEST

Generate Collection

Print

Search Results - Record(s) 1 through 2 of 2 returned.

1. Document ID: US 6184359 B1

L3: Entry 1 of 2

File: USPT

Feb 6, 2001

US-PAT-NO: 6184359

DOCUMENT-IDENTIFIER: US 6184359 B1

TITLE: Antibodies to epithelium-derived T-cell factor

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Grabstein; Kenneth H. Mercer Island WA
Anderson; Dirk M. Seattle WA
Eisenman; June R. Seattle WA
Fung; Victor Redmond WA

Rauch; Charles Bainbridge Island WA

US-CL-CURRENT: $\frac{530}{388.23}$; $\frac{424}{130.1}$, $\frac{424}{134.1}$, $\frac{424}{139.1}$, $\frac{424}{141.1}$, $\frac{424}{141.1}$, $\frac{424}{142.1}$, $\frac{424}{145.1}$, $\frac{424}{158.1}$, $\frac{435}{325}$, $\frac{435}{325}$, $\frac{435}{326}$, $\frac{435}{325}$,

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWC Draw Desc Image

2. Document ID: US <u>5892001</u> A

L3: Entry 2 of 2

File: USPT

Apr 6, 1999

US-PAT-NO: 5892001

DOCUMENT-IDENTIFIER: US 5892001 A

TITLE: Epithelium-derived T-cell factor antibodies


DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Grabstein; Kenneth H. Mercer Island WA
Anderson; Dirk M. Seattle WA
Eisenman; June R. Seattle WA
Fung; Victor Redmond WA
Rauch; Charles Bainbridge Island WA

US-CL-CURRENT: 530/387.9; 435/326, 435/331, 435/335, 530/388.1



Display Format: CIT Change Format

Previous Page Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US <u>6184359</u> B1

L2: Entry 1 of 1

File: USPT

Feb 6, 2001

US-PAT-NO: 6184359

DOCUMENT-IDENTIFIER: US 6184359 B1

TITLE: Antibodies to epithelium-derived T-cell factor

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Grabstein; Kenneth H.

Mercer Island

WA

Anderson; Dirk M.

Seattle

WA

Eisenman; June R.

Seattle Redmond WA WA

Fung; Victor Rauch; Charles

Bainbridge Island

WA

US-CL-CURRENT: 530/388.23; 424/130.1, 424/134.1, 424/139.1, 424/141.1, 424/142.1, 424/145.1, 424/158.1, 435/325, 435/326, 530/387.9, 530/388.1, 530/388.15, 530/389.1, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
D									

Generate Collection

Print

Terms	Documents
6184359	1

Display Format: CIT

Change Format

Previous Page

Next Page



Generate Collection

•

File: USPT

Print

Feb 5, 2002

US-PAT-NO: 6344192

L4: Entry 1 of 12

DOCUMENT-IDENTIFIER: US 6344192 B1

TITLE: Use of interleukin-15

DATE-ISSUED: February 5, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Grooten; Johan Adriaan Marc Lovendegem BEX
Dooms; Hans Peter Raf Ypres BEX
Fiers; Walter Charles Destelbergen BEX

US-CL-CURRENT: 424/85.2; 424/85.1, 435/386, 435/69.5, 435/69.52, 530/351, 930/140,

<u>930/141</u>

CLAIMS:

What is claimed is:

1. A method of stimulating formation and promoting survival of memory T cells which recognize a specific antigen in a mammal in need thereof, comprising:

administering IL-15 or active variants thereof capable of generating memory T-cells, wherein administration occurs after an ongoing immune response to said specific antigen to enhance the secondary/memory response elicited by a renewed contact with said antigen.

- 2. A method according to claim 1 for manipulating viability of memory cells generated after an ongoing immune response to said specific antigen and after clearance of said antigen.
- 3. A method according to claim 1 for manipulating responsiveness of memory cells to a new encounter with antigen.
- 4. A method according to claim 1, wherein responsiveness towards renewed antigen challenge of said memory cells is enhanced.
- 5. A method according to claim 1 for protecting ex vivo propagated T lymphocytes against cells death in absence of growth factor.
- 6. A method according to claim 1, wherein the memory cells are CD4.sup.+ T lymphocytes.
- 7. A pharmaceutical composition comprising ex vivo cultivated T lymphocytes, treated with IL-15 or active variants thereof, during the ex vivo cultivation procedure.